Rite Aid's CEO Discusses Q4 2012 Results - Earnings Call Transcript

Rite Aid (RAD)

Q4 2012 Earnings Call

April 12, 2012 8:30 am ET

Executives

Matt Schroeder - Group Vice President of Strategy & Investor Relations and Treasurer

John T. Standley - Chief Executive Officer, President, Director and Member of Executive Committee

Frank G. Vitrano - Chief Administrative Officer, Chief Financial Officer and Senior Executive Vice President

Analysts

Steven Forbes - Guggenheim Securities, LLC, Research Division

Carla Casella - JP Morgan Chase & Co, Research Division

Karru Martinson - Deutsche Bank AG, Research Division

Karen Eltrich - Goldman Sachs Group Inc., Research Division

Bryan C. Hunt - Wells Fargo Securities, LLC, Research Division

Matthew J. Fassler - Goldman Sachs Group Inc., Research Division

Lisa C. Gill - JP Morgan Chase & Co, Research Division

Mary Ross Gilbert - Imperial Capital, LLC, Research Division

Edward J. Kelly - Crédit Suisse AG, Research Division

Presentation

Operator

Good morning. My name is Tabitha, and I'll be your conference operator today. At this time, I'd like welcome everyone to the Rite Aid Fourth Quarter Fiscal 2012 Conference Call. [Operator Instructions] Mr. Schroeder, you may begin your conference.

Matt Schroeder

Thank you, Tabitha, and good morning, everyone. We welcome you to our Fourth Quarter Conference Call. On the call with me are John Standley, our President and Chief Executive Officer; and Frank Vitrano, our Chief Financial and Chief Administrative Officer. On today's call, John will give an overview of our fourth quarter results and discuss our business. Frank will discuss the key financial highlights and fiscal 2013 outlook. And then, we will take questions.

If you liked this article you might like

Walgreens Is Primed to Rally, With or Without Rite Aid

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

Walgreens to Tweak Number of Rite Aid Stores It Buys to Win Regulatory Approval

Will the FTC Let Walgreens Go on a $5.2 Billion Rite Aid Shopping Spree?